K
0.103
-0.56 (-84.44%)
| Penutupan Terdahulu | 0.662 |
| Jumlah Dagangan | 27,618,090 |
| Harga / Jualan (P/S) | 0.090 |
| Julat 52 Minggu |
| Margin Keuntungan | -43.99% |
| Margin Operasi (TTM) | -110.80% |
| EPS Cair (TTM) | -11.87 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -9.40% |
| Nisbah Semasa (MRQ) | 1.33 |
| Aliran Tunai Operasi (OCF TTM) | -122.75 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -72.22 M |
| Pulangan Atas Aset (ROA TTM) | -44.76% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Karyopharm Therapeutics Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.8 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -3.7 |
| Persekitaran Makro | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | -0.70 |
|
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.33% |
| % Dimiliki oleh Institusi | 42.78% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |